NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
公司代碼NGEN
公司名稱NervGen Pharma Corp
上市日期Mar 13, 2019
CEORogers (Adam H)
員工數量- -
證券類型Ordinary Share
年結日- -
公司地址Suite 1703 - 595 Burrard Street
城市VANCOUVER
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Canada
郵編V7X 1J1
電話16047225361
網址https://www.nervgen.com/
公司代碼NGEN
上市日期Mar 13, 2019
CEORogers (Adam H)